Title: Marked mucosal lipid shifts in treatment refractory inflammatory bowel disease: a
lipidomic study
Version: 3 Date: 23 Mar 2025
Reviewer's report:
I would like to thank the authors for taking the time to respond to all the questions.
As the authors acknowledge the potential for inaccurate estimation of the SES-CD score, I would
strongly recommend avoiding the use of SES-CD in this context. An alternative approach—
though less standardized—such as categorizing endoscopic findings as mild, moderate, or severe
based on the physician’s assessment, may be more appropriate for endoscopic reports in your
specific situation.
Title: Marked mucosal lipid shifts in treatment refractory inflammatory bowel disease: a
lipidomic study
Version: 3 Date: 23 Mar 2025
Reviewer's report:
I would like to thank the authors for taking the time to respond to all the questions.
As the authors acknowledge the potential for inaccurate estimation of the SES-CD score, I would
strongly recommend avoiding the use of SES-CD in this context. An alternative approach—
though less standardized—such as categorizing endoscopic findings as mild, moderate, or severe
based on the physician’s assessment, may be more appropriate for endoscopic reports in your
specific situation.
Please review this paper.
user
Title: Marked mucosal lipid shifts in treatment refractory inflammatory bowel disease: a
lipidomic study
Version: 3 Date: 23 Mar 2025
Reviewer's report:
I would like to thank the authors for taking the time to respond to all the questions.
As the authors acknowledge the potential for inaccurate estimation of the SES-CD score, I would
strongly recommend avoiding the use of SES-CD in this context. An alternative approach—
though less standardized—such as categorizing endoscopic findings as mild, moderate, or severe
based on the physician’s assessment, may be more appropriate for endoscopic reports in your
specific situation.
assistant